Pallas Capital Advisors LLC lessened its stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 5.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,029 shares of the life sciences company’s stock after selling 365 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Illumina were worth $806,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc increased its stake in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the last quarter. TD Private Client Wealth LLC grew its stake in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its position in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Illumina during the 2nd quarter worth about $61,000. Finally, Private Trust Co. NA lifted its holdings in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after buying an additional 212 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.
Illumina Stock Performance
NASDAQ ILMN opened at $136.48 on Wednesday. The company’s fifty day moving average is $140.55 and its two-hundred day moving average is $133.10. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a market capitalization of $21.65 billion, a price-to-earnings ratio of -13.70 and a beta of 1.11.
Analysts Set New Price Targets
ILMN has been the topic of a number of research reports. Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. raised their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Stephens upped their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Leerink Partners raised their target price on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, TD Cowen upped their price target on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.
Read Our Latest Stock Analysis on Illumina
Illumina Profile
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
- Five stocks we like better than Illumina
- 3 Monster Growth Stocks to Buy Now
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Consumer Staples Stocks, Explained
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Overbought Stocks Explained: Should You Trade Them?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.